Patents by Inventor Michael P. Neeper

Michael P. Neeper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANINE TRANSIENT RECEPTOR POTENTIAL V2 (CTRPV2) AND METHODS OF SCREENING FOR TRPV2 CHANNEL MODULATORS
    Publication number: 20110178274
    Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.
    Type: Application
    Filed: February 28, 2011
    Publication date: July 21, 2011
    Applicant: Janssen Pharmaceutica, N.V.
    Inventors: Ning QIN, Christopher M. Flores, Michael P. Neeper
  • Canine transient receptor potential V2 (cTRPV2) and methods of screening for TRPV2 channel modulators
    Patent number: 7897358
    Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: March 1, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ning Qin, Christopher M. Flores, Michael P. Neeper
  • Compositions And Methods For Identifying Modulars Of TRPV2
    Publication number: 20090275649
    Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.
    Type: Application
    Filed: July 9, 2009
    Publication date: November 5, 2009
    Inventors: Ning Qin, Yi Liu, Christopher M. Flores, Tasha Hutchinson, Michael P. Neeper
  • Compositions and methods for identifying modulators of TRPV2
    Patent number: 7575882
    Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: August 18, 2009
    Assignee: Janssen Pharmaceutica N. V.
    Inventors: Ning Qin, Yi Liu, Christopher M. Flores, Tasha Hutchinson, Michael P. Neeper
  • CANINE TRANSIENT RECEPTOR POTENTIAL V2 (CTRPV2) AND METHODS OF SCREENING FOR TRPV2 CHANNEL MODULATORS
    Publication number: 20090165151
    Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.
    Type: Application
    Filed: March 4, 2008
    Publication date: June 25, 2009
    Inventors: Ning Qin, Christopher M. Flores, Michael P. Neeper
  • Optimized expression of HPV 31 L1 in yeast
    Patent number: 7482428
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Ltd.
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Optimized expression of HPV 31 L1 in yeast
    Publication number: 20080166371
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Application
    Filed: July 19, 2007
    Publication date: July 10, 2008
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Optimized expression of HPV31 L1 in yeast
    Patent number: 7276243
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: October 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Synthetic human papilloma virus genes
    Patent number: 7211569
    Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
  • Synthetic human papillomavirus genes
    Patent number: 7001995
    Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: February 21, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
  • Protein delivery system using human papillomavirus virus-like particles
    Patent number: 6991795
    Abstract: Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: January 31, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Lowe, Kathrin U. Jansen, Joseph G. Joyce, William L. McClements, James C. Cook, III, Jessica Ching-Yee Ling, Michael P. Neeper
  • DNA encoding human papilloma virus type 18
    Patent number: 6908615
    Abstract: The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: June 21, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George
  • Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein
    Patent number: 6159729
    Abstract: The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 12, 2000
    Assignee: Merck & Co., Ltd.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George, E. Dale Lehman
  • DNA encoding human papillomavirus type 18
    Patent number: 5840306
    Abstract: The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: November 24, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper
  • Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
    Patent number: 5821087
    Abstract: The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Robert Lowe, Joseph G. Joyce, Hugh A. George, Kathryn J. Hofmann, Kathrin U. Jansen, E. Dale Lehman, Michael P. Neeper
  • Recombinant human papillomavirus type 18 vaccine
    Patent number: 5820870
    Abstract: The present invention is directed to vaccines for human papillomavirus type 18 and derivatives thereof.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Joyce, Hugh A. George, Kathryn J. Hofman, Kathrin U. Jansen, Michael P. Neeper
  • Processes for making proteins having anticoagulant properties
    Patent number: 5328997
    Abstract: Proteins which specifically inhibit coagulation Factor Xa. The inhibitors, which do not inhibit Factor VIIa, kallikrein, trypsin, chymotrypsin, thrombin, urokinase, tissue plasminogen activator, plasmin, elastase, Factor XIa or S. aureus V8 protease, are polypeptides of 60 amino acid residues. The inhibitors may be purified from Ornithodoros moubata extract, synthesized, or produced using a recombinant DNA yeast expression system.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: July 12, 1994
    Assignee: Merck & Co., Inc.
    Inventors: George P. Vlasuk, Lloyd H. Waxman, Victor M. Garsky, Michael P. Neeper
  • Proteins having anticoagulant properties
    Patent number: 5239058
    Abstract: Proteins which specifically inhibit coagulation Factor Xa. The inhibitors, which do not inhibit Factor VIIa, kallikrein, trypsin, chymotrypsin, thrombin, urokinase, tissue plasminogen activator, plasmin, elastase, Factor XIa or S. aureus V8 protease, are polypeptides of 60 amino acid residues. The inhibitors may be purified from Ornithodoros moubata extract, synthesized, or produced using a recombinant DNA yeast expression system.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: August 24, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George P. Vlasuk, Lloyd H. Waxman, Victor M. Garsky, Michael P. Neeper